3-<2-<2-(癸氧基)乙氧基>乙氧基>-1,2-丙二醇 | 102421-58-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 3-<2-<2-(癸氧基)乙氧基>乙氧基>-1,2-丙二醇
• 英文名称: 3-<2-<2-(decyloxy)ethoxy>ethoxy>-1,2-propanediol
• 英文别名: 3-[2-[2-(Decyloxy)ethoxy]ethoxy]-1,2-propanediol；3-{2-[2-(decyloxy)ethoxy]ethoxy}-1,2-propanediol；3-[2-(2-Decoxyethoxy)ethoxy]propane-1,2-diol
• CAS: 102421-58-9
• 化学式: C₁₇H₃₆O₅
• 分子量: 320.47
• InChiKey: UXOFKSMAOXMVGV-UHFFFAOYSA-N

物化性质

• 沸点：
  441.3±35.0 °C(Predicted)
• 密度：
  0.990±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-<2-<2-(癸氧基)乙氧基>乙氧基>-1,2-丙二醇 在 吡啶 、 Amberlyst-15 ion-exchange resin 、 sodium acetate 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 氯仿 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 8.5h， 生成 4-hydroxy-N,N,N-trimethyl-7-(phenylmethoxy)-3,5,9,12,15-pentaoxa-4-phosphapentacosan-1-aminium, 4-oxide, hydroxide, inner salt
  参考文献：
  名称：

  Analogs of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain

  摘要：

  Racemic analogues of platelet activating factor (PAF) in which the alkoxy chain (R = -O(CH2)15CH3) has been replaced with a chain containing multiple ether linkages near the end (17, R = -O(CH2)8O(CH2)2O(CH2)2OCH3) or at the beginning (18, R = -O(CH2)2O(CH2)2O(CH2)9CH3) of the chain have been prepared. Both compounds exhibit reduced hypotensive and platelet aggregation responses compared to racemic C16-PAF (1a). This reduction in the biological activities is more apparent when the new oxygen atoms are located near the end of the chain. This substitution of additional oxygen atoms into the alkoxy chain does not result in any dramatic gains in selectivity of the biological responses.

  DOI：

  10.1021/jm00157a038
• 作为产物：
  描述：

  二聚乙二醇单癸醚 在 吡啶 、 硫酸 作用下， 以 N-甲基乙酰胺 、 甲醇 、 正己烷 、 水 为溶剂， 生成 3-<2-<2-(癸氧基)乙氧基>乙氧基>-1,2-丙二醇
  参考文献：
  名称：

  Antihypertensive phosphate derivatives

  摘要：

  描述具有以下公式的降压磷酸衍生物：##STR1## 其中W从由甲基和苯组成的基团中选择，该基团可以选择性地被C.sub.1 -C.sub.3烷基，C.sub.1 -C.sub.3烷氧基和苯基取代；r、n、m和a是整数，使得表达式r+(n+1)m+a也是整数，并且其值为3到20；r大于或等于2；n大于或等于2；m大于或等于零且a大于或等于零；T从氢和##STR2## 中选择，其中R.sub.1从氢，C.sub.1 -C.sub.4支链或直链烷基，C.sub.1 -C.sub.4支链或直链烷氧基和C.sub.1 -C.sub.4支链或直链烷基氨基组成的基团中选择；Q是从--(CH.sub.2).sub.p --和--(CHR).sub.p --中选择的二价基团，其中p是整数2-12，而基团--(CHR).sub.p --代表一个被一个或多个C.sub.1 -C.sub.10烷基或苯基取代的烷基链；Z从##STR3## 中选择，其中R.sub.2可以相同也可以不同，并且从氢和C.sub.1 -C.sub.4支链或直链烷基中选择，q是一个整数从4-7；可以是消旋的或光学活性形式。

  公开号：

  US04703130A1

文献信息

• Analogs of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor
  作者：A. Wissner、M. L. Carroll、K. E. Green、S. S. Kerwar、W. C. Pickett、R. E. Schaub、L. W. Torley、S. Wrenn、C. A. Kohler

  DOI：10.1021/jm00087a023

  日期：1992.5

  A series of aryl phosphoglyceride (3, 19-6 1) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared. A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. Selected compounds were also evaluated for their ability to displace [H-3]PAF from its receptor on rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.
• US4703130A
  申请人：——

  公开号：US4703130A

  公开（公告）日：1987-10-27
• US4939127A
  申请人：——

  公开号：US4939127A

  公开（公告）日：1990-07-03
• Antihypertensive phosphate derivatives
  申请人：American Cyanamid Company

  公开号：US04703130A1

  公开（公告）日：1987-10-27

  Antihypertensive phosphate derivatives having the following formula are described: ##STR1## wherein W is selected from the group consisting of methyl and phenyl optionally substituted with C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and phenyl; r, n, m and a are integers such that the expression r+(n+1)m+a is also an integer and has a value of 3 to 20; r is greater than or equal to 2; n is greater than or equal to 2; m is greater than or equal to zero and a is greater than or equal to zero; T is selected from the group consisting of hydrogen and ##STR2## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino; Q is a bivalent radical selected from --(CH.sub.2).sub.p -- and --(CHR).sub.p --, wherein p is an integer 2-12 and the moiety --(CHR).sub.p -- represents an alkylene chain which is substituted by one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups; Z is selected from the group consisting of ##STR3## wherein R.sub.2 may be the same or different and is selected from the group consisting of hydrogen and C.sub.1 -C.sub.4 branched or straight chain alkyl and q is an integer from 4-7; in either the racemic or optically active forms.

  描述具有以下公式的降压磷酸衍生物：##STR1## 其中W从由甲基和苯组成的基团中选择，该基团可以选择性地被C.sub.1 -C.sub.3烷基，C.sub.1 -C.sub.3烷氧基和苯基取代；r、n、m和a是整数，使得表达式r+(n+1)m+a也是整数，并且其值为3到20；r大于或等于2；n大于或等于2；m大于或等于零且a大于或等于零；T从氢和##STR2## 中选择，其中R.sub.1从氢，C.sub.1 -C.sub.4支链或直链烷基，C.sub.1 -C.sub.4支链或直链烷氧基和C.sub.1 -C.sub.4支链或直链烷基氨基组成的基团中选择；Q是从--(CH.sub.2).sub.p --和--(CHR).sub.p --中选择的二价基团，其中p是整数2-12，而基团--(CHR).sub.p --代表一个被一个或多个C.sub.1 -C.sub.10烷基或苯基取代的烷基链；Z从##STR3## 中选择，其中R.sub.2可以相同也可以不同，并且从氢和C.sub.1 -C.sub.4支链或直链烷基中选择，q是一个整数从4-7；可以是消旋的或光学活性形式。
• Analogs of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain
  作者：A. Wissner、C. A. Kohler、B. M. Goldstein

  DOI：10.1021/jm00157a038

  日期：1986.7

  Racemic analogues of platelet activating factor (PAF) in which the alkoxy chain (R = -O(CH2)15CH3) has been replaced with a chain containing multiple ether linkages near the end (17, R = -O(CH2)8O(CH2)2O(CH2)2OCH3) or at the beginning (18, R = -O(CH2)2O(CH2)2O(CH2)9CH3) of the chain have been prepared. Both compounds exhibit reduced hypotensive and platelet aggregation responses compared to racemic C16-PAF (1a). This reduction in the biological activities is more apparent when the new oxygen atoms are located near the end of the chain. This substitution of additional oxygen atoms into the alkoxy chain does not result in any dramatic gains in selectivity of the biological responses.